China Yct International Group (CYIG) Return on Equity ROE from the third quarter 2019 to third quarter 2018 and annually, average high and low, overall ranking from Dec 31 2018 to Dec 31 2017 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
China Yct International Group, Inc.  (CYIG)

China Yct International Group's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for China Yct International Group in the third quarter 2019?
China Yct International Group, Inc. achieved a return on average equity (ROE) of 14.67 % in its third quarter 2019, this is above CYIG's average return on equity of 13.74%.
China Yct International Group, Inc. shareholder's equity over the 12 months ending in its third quarter 2019 are valued at $109 million

ROE has advanced compared to 13.52% in the second quarter 2019, due to net income growth.

Within the Major Pharmaceutical Preparations industry 35 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2019 from 1049 to 1337.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2018)
III. Quarter		 (Sep 30 2018)
II. Quarter		 (Jun 30 2018)
I. Quarter		 (Mar 31 2018)
IV. Quarter		 (Dec 31 2017)
III. Quarter
Y / Y Equity Change 10.44 % 13.76 % 18.82 % 27.42 % -
Y / Y Net Income Change 56.37 % 82.42 % 17.8 % -32.15 % 10.59 %
Net Income (TTM) in Millions 16 14 12 12 13
Return On Equity (TTM) 14.67 % 13.52 % 12.09 % 11.91 % 14 %
CYIG's Total Ranking # 1337 # 1049 # 1142 # 1171 # 1044
Equity (TTM) in Millions 112 107 107 108 102
Seq. Equity Change 4.43 % 0.08 % -0.8 % 6.54 % 7.56 %
Seq. Net Income Change 6.41 % -9.1 % 75.05 % -7.66 % 24.14 %

Back to CYIG Management Effectiveness >> CYIG's 5 Years Annual ROE >> Compare CYIG ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 36
Sector # 79
Overall # 1337

Return On Equity Statistics
High Average Low
93.49 %
13.74 %
-49.36 %
(Mar 31 2013)   (Jun 30 2012)





CYIG Annual Return On Equity (Mar 31 2018)
2018		 (Mar 31 2017)
2017		 (Mar 31 2016)
2016		 (Mar 31 2015)
2015		 (Mar 31 2014)
2014
Total Equity in Millions 108 85 80 75 66
Y / Y Equity Change 27.42 % 5.64 % 6.55 % 13.61 % 15.61 %
Net Income in Millions 12 10 8 9 8
Y / Y Net Income Change 16.75 % 19.46 % -5.33 % 9.48 % -0 %
Return On Equity 10.85 % 11.85 % 10.48 % 11.79 % 12.24 %

Back to CYIG Management Effectiveness >> CYIG's 5 Years Annual ROE >> Compare CYIG ROE to its Competitors




Annual Roe Comment
In 2018 ROE fell to 10.85 %, despite net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CYIG's' Return on Equity at Yahoo Finance
CYIG's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CYIG's Competitors
Subscribers only: Roe for China Yct International Group's Suppliers
Subscribers only: Return On Equity for CYIG's Customers




Companies with similar Return On Equity at Dec 31 2018, within Healthcare Sector ROE
Phibro Animal Health Corporation  39.07 %
Bristol myers Squibb Company  37.19 %
Chemed Corporation  36.99 %
Molecular Templates Inc   35.61 %
Stryker Corp  35.29 %
Biogen Inc   33.71 %
Align Technology inc   33.41 %
Regeneron Pharmaceuticals Inc   32.19 %
Waters Corporation  31.53 %
Corcept Therapeutics Inc  30.34 %
Tivity Health Inc   29.71 %
Lifevantage Corp  29.37 %
Abiomed Inc   29.03 %
Supernus Pharmaceuticals inc   27.45 %
Ionis Pharmaceuticals Inc   27.34 %
Radnet Inc   27.10 %
Amedisys Inc  25.47 %
Alpha Pro Tech Ltd   25.29 %
Eli Lilly And Company  25.22 %
Encompass Health Corporation  25.13 %
Gilead Sciences Inc   25.12 %
Agilent Technologies inc   24.88 %
Regenxbio Inc   24.68 %
Psychemedics Corporation  24.55 %
Johnson and Johnson  24.42 %
Ligand Pharmaceuticals Incorporated  24.28 %
Icon Plc  23.82 %
Varian Medical Systems Inc   23.53 %
Enanta Pharmaceuticals Inc  23.29 %
Biospecifics Technologies Corp  23.01 %

Date modified: 2026-09-08T15:09:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.